TNF Pharmaceuticals held its annual meeting on November 25, 2024, where stockholders approved an amendment to increase the number of shares available under the 2021 Equity Incentive Plan by 2,259,060 shares, totaling 2,500,000 shares. Additionally, seven directors were re-elected, and the appointment of the accounting firm Stephano Slack LLC was ratified for the fiscal year 2024.